Maria E. Balasis

2.7k total citations · 1 hit paper
35 papers, 1.8k citations indexed

About

Maria E. Balasis is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Maria E. Balasis has authored 35 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 16 papers in Molecular Biology and 16 papers in Genetics. Recurrent topics in Maria E. Balasis's work include Acute Myeloid Leukemia Research (18 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Maria E. Balasis is often cited by papers focused on Acute Myeloid Leukemia Research (18 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Maria E. Balasis collaborates with scholars based in United States, Germany and China. Maria E. Balasis's co-authors include Kapil N. Bhalla, Michael Pranpat, Warren Fiskus, Kathy Rocha, Purva Bali, Sandhya Kumaraswamy, Sandhya Boyapalle, Peter Atadja, Fei Guo and Edward Seto and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Maria E. Balasis

34 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

2005 644 citations Purva Bali, Michael Pranpat et al. Journal of Biological Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maria E. Balasis United States	14	1.3k	578	350	314	127	35	1.8k
Kathy Rocha United States	7	1.1k 0.9×	368 0.6×	169 0.5×	261 0.8×	106 0.8×	13	1.3k
Paul M. Ayton United States	15	2.1k 1.6×	1.2k 2.1×	184 0.5×	483 1.5×	169 1.3×	17	2.6k
Francisco Adrián United States	15	714 0.6×	413 0.7×	275 0.8×	386 1.2×	264 2.1×	30	1.7k
Alexandra E. Irvine United Kingdom	20	825 0.6×	336 0.6×	136 0.4×	288 0.9×	216 1.7×	46	1.3k
Dilara McCauley United States	18	1.3k 1.0×	350 0.6×	151 0.4×	456 1.5×	120 0.9×	56	1.7k
Valérie Lagarde France	14	414 0.3×	710 1.2×	508 1.5×	254 0.8×	117 0.9×	27	1.2k
Meng Ling Choong Singapore	14	693 0.5×	265 0.5×	284 0.8×	168 0.5×	97 0.8×	24	1.0k
Michael Pranpat United States	6	1.1k 0.9×	252 0.4×	121 0.3×	251 0.8×	94 0.7×	11	1.3k
Veronica Novotny‐Diermayr Singapore	14	596 0.5×	225 0.4×	224 0.6×	380 1.2×	133 1.0×	19	986
Audie Rice United States	17	832 0.6×	535 0.9×	105 0.3×	660 2.1×	334 2.6×	28	1.7k

Countries citing papers authored by Maria E. Balasis

Since Specialization

Citations

This map shows the geographic impact of Maria E. Balasis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria E. Balasis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria E. Balasis more than expected).

Fields of papers citing papers by Maria E. Balasis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria E. Balasis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria E. Balasis. The network helps show where Maria E. Balasis may publish in the future.

Co-authorship network of co-authors of Maria E. Balasis

This figure shows the co-authorship network connecting the top 25 collaborators of Maria E. Balasis. A scholar is included among the top collaborators of Maria E. Balasis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria E. Balasis. Maria E. Balasis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Padron, Eric, Wenyi Fan, Sara Tinsley, et al.. (2024). Reduction in MPN-Total Symptom Score (TSS) Is Associated with Overall Survival (OS) in Chronic Myelomonocytic Leukemia (CMML). Blood. 144(Supplement 1). 6750–6750. 1 indexed citations

Ferrall‐Fairbanks, Meghan C., Brian Johnson, Christopher T. Letson, et al.. (2022). Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes. Blood Cancer Discovery. 3(6). 536–553. 9 indexed citations

Balasis, Maria E., Traci Kruer, Lei Sun, et al.. (2022). The Long Non-Coding RNA MALAT1 Is Necessary for Hematopoietic Stem and Progenitor Cell Expansion and Preleukemic Myeloproliferation in TET2 Deficient Myeloid Neoplasms. Blood. 140(Supplement 1). 1991–1993. 1 indexed citations

Patnaik, Mrinal M., David A. Sallman, Abhishek A. Mangaonkar, et al.. (2020). Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 136(7). 909–913. 31 indexed citations

Patnaik, Mrinal M., David A. Sallman, Abhishek A. Mangaonkar, et al.. (2019). A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML). Blood. 134(Supplement_1). 4234–4234. 3 indexed citations

Niyongere, Sandrine, Nolwenn Lucas, Anthony D. Pomicter, et al.. (2018). Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 33(1). 205–216. 29 indexed citations

Padron, Eric, Amy E. DeZern, Sandrine Niyongere, et al.. (2017). Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia. Blood. 130. 162–162. 14 indexed citations

Ball, Markus, Yonggang Zhao, Maria E. Balasis, et al.. (2017). Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia. Leukemia. 32(2). 532–538. 1 indexed citations

Padron, Eric, Amy E. DeZern, Marcio Andrade‐Campos, et al.. (2016). A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clinical Cancer Research. 22(15). 3746–3754. 62 indexed citations

10.

Niyongere, Sandrine, Nolwenn Lucas, Christopher Cubitt, et al.. (2016). Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML). Blood. 128(22). 109–109. 1 indexed citations

11.

Gillis, Nancy, Markus Ball, Qing Zhang, et al.. (2016). Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. The Lancet Oncology. 18(1). 112–121. 199 indexed citations

12.

Padron, Eric, Amy E. DeZern, Kris Vaddi, et al.. (2015). A multi-institution phase I trial of ruxolitinib in chronic myelomonocytic leukemia (CMML).. Journal of Clinical Oncology. 33(15_suppl). 7021–7021. 1 indexed citations

13.

Li, Rongshi, Chunwei Cheng, Maria E. Balasis, et al.. (2014). Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors. European Journal of Medicinal Chemistry. 90. 315–331. 23 indexed citations

14.

Berndt, Norbert, et al.. (2013). Akt2 and acid ceramidase cooperate to induce cell invasion and resistance to apoptosis. Cell Cycle. 12(13). 2024–2032. 7 indexed citations

15.

Balasis, Maria E., Kenichiro Doi, Norbert Berndt, et al.. (2012). Synthesis and evaluation of substituted hexahydronaphthalenes as novel inhibitors of the Mcl-1/BimBH3 interaction. Bioorganic & Medicinal Chemistry Letters. 22(18). 5961–5965. 4 indexed citations

16.

Balasis, Maria E., Y. Ann Chen, William J. Fulp, et al.. (2011). Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice. Clinical Cancer Research. 17(9). 2852–2862. 55 indexed citations

17.

Fiskus, Warren, Michael Pranpat, Maria E. Balasis, et al.. (2006). Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells. Clinical Cancer Research. 12(19). 5869–5878. 81 indexed citations

18.

Bali, Purva, Michael Pranpat, Ramona F. Swaby, et al.. (2005). Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2. Clinical Cancer Research. 11(17). 6382–6389. 156 indexed citations

19.

Bali, Purva, Michael Pranpat, James E. Bradner, et al.. (2005). Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90. Journal of Biological Chemistry. 280(29). 26729–26734. 644 indexed citations breakdown →

20.

Fiskus, Warren, Purva Bali, Michael Pranpat, et al.. (2005). Co-Treatment with a Novel Heat Shock Protein (hsp) 90 Inhibitor IPI504 and the Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Wild Type or Mutant Bcr-Abl-T315I or FLT-3-ITD-Containing Human Leukemia Cells.. Blood. 106(11). 4461–4461. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact